Pfizer's Profit Forecast for 2025 Signals Hope Amid Shareholder Concerns and Strategic Overhaul

In a bid to ease the unease among investors, Pfizer (NYSE: PFE) has projected its profit for 2025 to align closely with market anticipations. This update comes as shareholders, including the notable hedge fund Starboard, have raised concerns regarding the pharmaceutical giant’s strategy for revitalizing its operations. Following this announcement, Pfizer’s stock made a promising leap of nearly 3%, reaching $25.98 in premarket trading.

Forecasts indicate that Pfizer’s revenues from its COVID-19 vaccine and treatment will likely mirror current-year figures, an important detail considering the company's struggle to offset diminishing income from blockbuster drugs that are approaching patent expiration. The company has seen its shares plummet nearly 12% in 2023, trading at less than half their peak value during the COVID-19 pandemic mania.

Recent weeks have not been kind to Pfizer, with analysts consistently downgrading their profit expectations for the company. Criticism peaked when Starboard pointed fingers at Pfizer's management, accusing them of overspending on major acquisitions without delivering corresponding profitable new drug developments.

CEO Albert Bourla has defended the company’s approach, citing ongoing initiatives to streamline operations and divest non-essential units to manage its debt more effectively. While JP Morgan analyst Chris Schott has noted that certain assets in Pfizer’s pipeline, especially in oncology, could enhance the company’s narrative, he believes substantial progress needs to occur post-2026 to shift the current sentiment around its stock.

Specifically, Pfizer anticipates an adjusted profit between $2.80 and $3 per share, closely tracking analysts' average estimate of $2.88 per share. They are also forecasting expected revenues for 2025 to range from $61 billion to $64 billion, just shy of the consensus estimate of $63.26 billion. Although the path presents challenges, BMO Capital Markets’ analyst Evan Seigerman labeled Pfizer's forecast as “reasonable and achievable,” suggesting room for potential upward adjustments as the year unfolds.

Additionally, the company is bracing for about a $1 billion impact on revenues due to adjustments in Medicare’s Part D prescription program, instituted under President Biden's Inflation Reduction Act. The anticipated changes, characterized by new manufacturer discounts, are expected to outweigh benefits, such as the forthcoming $2,000 out-of-pocket spending cap for seniors participating in the prescription drug program next year.

As Pfizer prepares for an analyst conference call later today to delve deeper into these projections, traders will be keenly watching how the company outlines its strategy to navigate challenges while striving for recovery and growth.